Randomized, Split-Side, Double Blinded, Placebo-Controlled study, the Efficacy of Intralesional Injection of Botulinum Toxin Type A versus 0.9% NaCl for the Treatment of Scalp Psoriasis

Phase 3

Recruiting

• Conditions: - Psoriasis with scalp involvement; Botulinum toxin; Onabotulinum toxin; Scalp psoriasis; Scalp- modified Psoriasis Area and Severity Index

• Registration Number: TCTR20181214001
• Lead Sponsor: The Royal College Physicians of Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-12-14
• Study Completion: 2019-03-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

- Age 18-60
- Diagnosed psoriasis by clinical or histopathology with scalp involvement
- lesion of scalp psoriasis at least 16 cm2 area both side of scalp
- all participants are informed consent

Exclusion Criteria

- There are other scalp conditions
- Pregnancy or lactation
- Botulinum toxin A, human albumin of lactose allergy
- There is medical condition eg. myasthenia gravis, amyotrophic lateral sclerosis
- Tendency to bleeding
- Currently use aminoglycosides

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mean difference change in modified Psoriasis Severity Index week 0,2,4,8,12 scoring

Secondary Outcome Measures

Name	Time	Method
Sebum production week 0,2,4,8,12 Sebumeter,Sweat production week 0,2,4,8,12 Iodine starch test, hyperhidrosis Disease Severity Scale,Quality of life week 0,2,4,8,12 Questionnaire (Dermatology life quality index),itching symptom week 0,2,4,8,12 Visual analogue scale